- Multiomic AI for early cancer signals
- Blood-based screening approach in practice today
- Active colorectal and other cancer programs
Freenome
Multiomic AI for early cancer detection
SF7.9
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Interpret genomic test results in context
Interpret genomic test results in context
Best for
Health systems and screening payer programs
Pricing
Custom
SoftFinders Score
7.9 / 10
Overview
What is Freenome?
Freenome is a multiomics platform for health systems and screening programs, applying AI to blood samples for early cancer detection across colorectal and other cancer pathways.
- Clinical role: It supports genomic interpretation and precision-care workflows rather than standalone conclusions, so clinical context remains essential when teams act on findings.
- Screening focus: The platform centers on multiomic signals for blood-based screening, with active programs spanning colorectal and other cancer areas.
- Evaluation priorities: Buyers should confirm the test menu, turnaround times, EHR result delivery, interpretation support, and clearance for each intended indication.
- Commercial model: Pricing is sales-led and buyer-specific rather than publicly posted, while implementation requires integration planning and review.
Freenome is best assessed as a screening and precision-medicine layer whose fit depends on indication, readiness, and care pathways.
KEY FEATURES
What you get out of the box
Genomic Interpretation
Interprets genomic test results in context
Multiomics Analysis
Analyzes multiple omics data layers together
Cancer Detection
Supports early cancer detection workflows
Biomarker Discovery
Surfaces biomarker signals across data
Clinical Trials
Connects insights with clinical trial options
Precision Care
Supports precision-care decisions across patient populations
USE CASES
Where teams put it to work
Interpret genomic test results in context
Support early cancer detection programs
Surface biomarker signals across data
Connect genomic insights with care decisions
Support precision oncology workflows
Bridge genomic data and clinical trials
Editorial Take
What we like, and what to verify
- Clearance scope varies by indication
- Coverage and reimbursement are evolving
- Programs require buyer commitment to scale
Screenshots
A look inside
Freenome homepage screenshotAlternatives
Tools to consider next
Tempus SF 8.3
Why consider it
Precision medicine platform across data and AI
GRAIL SF 8
Why consider it
Multi-cancer early detection from blood
Abridge SF 8.8
Why consider it
Generative AI scribe for health systems
Nuance DAX Copilot SF 8.7
Why consider it
Microsoft and Nuance enterprise ambient scribe
Suki AI SF 8.4
Why consider it
Voice-driven AI scribe and EHR assistant
Nabla Copilot SF 8.4
Why consider it
Ambient AI scribe for independent clinicians
FAQ